Lupin Limited
LUPIN
Κατάταξη σε μετοχές
#2104
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
Τιμή μετοχής
$21.43
Κεφαλαιοποίηση
$9.80B
Αλλαγή (1 ημέρα)
0.14%
Αλλαγή (1 έτος)
-2.88%
Χώρα
IN
Εμπόριο Lupin Limited (LUPIN)
Κατηγορία
Healthcare
Κέρδη για την Lupin Limited (LUPIN)
Κέρδη τον Jun 2026 TTM: $824.86M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Lupin Limited, τα τρέχοντα κέρδη της εταιρείας είναι $824.86M. Το 2024, η εταιρεία παρουσίασε κέρδη $290.50M, αύξηση σε σχέση με των κερδών του 2023 που ήταν $87.18M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Lupin Limited από 2004 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $824.86M | 75.71% |
| 2025 | $469.45M | 61.60% |
| 2024 | $290.50M | 233.20% |
| 2023 | $87.18M | -148.23% |
| 2022 | $-180.77M | -178.93% |
| 2021 | $229.01M | 127.84% |
| 2020 | $100.52M | -50.46% |
| 2019 | $202.90M | 141.60% |
| 2018 | $83.98M | -84.63% |
| 2017 | $546.37M | 8.74% |
| 2016 | $502.47M | -8.18% |
| 2015 | $547.26M | -3.94% |
| 2014 | $569.71M | 60.84% |
| 2013 | $354.21M | 50.17% |
| 2012 | $235.88M | 5.71% |
| 2011 | $223.13M | 19.92% |
| 2010 | $186.07M | 55.87% |
| 2009 | $119.38M | -11.57% |
| 2008 | $135.00M | 43.62% |
| 2007 | $93.99M | 85.65% |
| 2006 | $50.63M | 132.81% |
| 2005 | $21.75M | -50.60% |
| 2004 | $44.02M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 113.92% |
IN
|
